



Shedir Pharma Group S.p.A.

• PRESS RELEASE •

European Wellflu® patent awarded

Piano di Sorrento (NA), 1st August 2019 – Shedir Pharma Group S.p.A. (“Shedir Pharma Group” or the “Company” or “Issuer”), holding company of the Shedir Pharma group, leader in the healthcare sector (nutraceutical and pharmaceutical), announces the decision of the European Patent Office (EPO) to award the European patent for Wellflu® (*Pharmaceutical composition comprising cetraria islandica ach., sodium hyaluronate and a saline solution for treating ailments of the respiratory system*) marketed in Italy in the medical devices Flubexin® A iso vial and Flubexin® A 3 vial.

The Wellflu® patent is to be found in the respiratory sector, and boasts specific functions in the case of respiratory tract disorders both in adults and children. Its effectiveness has already been scientifically demonstrated through experimental studies conducted with the Università di Napoli Federico II.

This achievement gives further prestige to the Wellflu® patent (the Italian patent already obtained in January 2019) and to the associated brand, as well as guaranteeing protection of the innovation for 20 years throughout Europe.

This recognition is furthermore a reward for the group’s efforts in research and development of innovative products in the respiratory field, where it is already present with other top brands such as Shedirflu®.

With the award of this patent, the number of patents held by the group has increased to eight. It should further be noted that the group has around 50 patents pending in Italy.



Shedir Pharma Group S.p.A., is the holding company of the Shedir Pharma group, active in the nutraceutical and pharmaceutical sector and specialised in research, formulation, development and marketing of nutraceutical, dermocosmetic and pharmaceutical products and medical devices. Shedir Pharma S.r.l. Unipersonale, the subsidiary company, is a Borsa Italiana 'Elite' company.

The Shedir Pharma group develops and markets functional products in around 15 therapeutic areas (for example cardiology, respiratory, osteoarticular, urological, paediatric, gynaecological, neurological and algological), through a structured network of around 800 exclusive sales agents and directly to top wholesalers who then independently supply pharmacies and parapharmacies. Thanks to the work of its research and development team, and to collaborations with the most important Italian Universities and private research institutions, it is committed to a continuous search for innovation, with the formulation of unique, patent-protected formulations. Product innovation and effectiveness is further supported by published scientific studies. SHEDIRPHARMA® GROUP S.p.A. is also active in the veterinary market with the Shedir® Pet line, a product line developed for the specific needs of animals. The group holds 2 quality certifications that allow constant monitoring through all phases – research, development and marketing of the products.

For further information:

- Shedir Pharma Group S.p.A. •

Investor Relator

tel: +39 081 19910422

e.mail: investor.relations@shedirpharmagroup.com

- BPER Banca S.p.A. •

Nominated Adviser

tel: +39 059 2021140

e.mail: shedir@bper.it